Search Results
Your search for ,200 matches 1534 pages
Showing 1501 - 1534Glutamine Ratio Is Key Indicator of Tumor Aggression in Ovarian Cancer, Study Finds
An analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize. The study, which was published in Molecular Systems Biology, also suggests how ovarian cancer treatments can be tailored based on...
High Preoperative Hepatitis B Surface Antigen Level Predicts Hepatocellular Carcinoma Recurrence in Patients With Low HBV DNA
In a Chinese study reported in JAMA Surgery, Huang et al found that preoperative elevated hepatitis B virus (HBV) surface antigen (HBsAg) level is an independent risk factor for hepatocellular carcinoma recurrence and mortality in patients with low HBV DNA levels undergoing hepatic resection....
Modafinil Not Better Than Placebo for Fatigue in Lung Cancer Patients
In a trial reported in the Journal of Clinical Oncology, Spathis et al found that that the central nervous system (CNS) stimulant modafinil had no effect on fatigue compared with placebo in patients with advanced non–small cell lung cancer (NSCLC). Fatigue improved in both groups during the...
Human Papillomavirus Vaccine Proves Effective in Women With HIV
Women infected with HIV are disproportionally affected by human papillomavirus (HPV)-related anogenital disease, particularly with increased immunosuppression. In a clinical study of 319 HIV-infected women in the United States, Brazil, and South Africa, researchers assessed the immunogenicity and...
Gene Signatures Identified by Meta-Analysis Predict Survival and Suboptimal Debulking in Late-Stage Ovarian Cancer
As reported in the Journal of the National Cancer Institute, Riester et al have identified gene-expression signatures predictive of survival and debulking status in late-stage ovarian cancer. Study Details The study involved meta-analytic techniques using integrated data from 13 publicly...
Study Finds Routine Mammograms Offer Limited Benefit to Oldest Female Patients
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another decade, according to a review published online in JAMA by Walter and...
Preclinical Study Suggests Benefits of Increased Tumor Perfusion and Reduced Tumor Hypoxia With Exercise in Prostate Cancer
In a study reported in the Journal of the National Cancer Institute, McCullough et al used an orthotopic rat model of prostate cancer to assess the effects of exercise on tumor hemodynamics and tissue hypoxia. Their findings of enhanced tumor perfusion and diminished tumor hypoxia suggest that...
Continued Survival Benefits With Radical Prostatectomy in Longer-Term Follow-up in Scandinavian Prostate Cancer Group-4 Trial
As reported in The New England Journal of Medicine by Bill-Axelson et al, additional long-term follow-up in the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) continues to show significant benefits of radical prostatectomy vs watchful waiting in early prostate cancer, including reduced risk of ...
Bevacizumab Added to Radiotherapy/Temozolomide Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Glioblastoma
In a double-blind phase III trial reported in The New England Journal of Medicine, Chinot et al assessed adding bevacizumab (Avastin) to radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. This was the second of two similar studies published in the February 20 issue of...
Pathologic Complete Response Has Prognostic Value in Breast Cancer, But Is Not Supported as Surrogate for Event-Free or Overall Survival
Pathologic complete response has been proposed as a surrogate endpoint for long-term clinical benefit in breast cancer. The U.S. Food and Drug Administration (FDA) established the international Collaborative Trials in Neoadjuvant Breast Cancer working group to perform a pooled analysis of...
Antifungal Itraconazole Shows Activity in Basal Cell Carcinoma
In an open-label exploratory phase II trial reported in the Journal of Clinical Oncology, Kim et al found that the antifungal agent itraconazole, which inhibits the Hedgehog signaling pathway, reduced tumor cell proliferation, Hedgehog pathway activity, and tumor area in patients with basal cell...
Yoga Improves Inflammation, Fatigue, and Vitality in Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Kiecolt-Glaser et al found that yoga reduced levels of inflammatory cytokines and fatigue and increased vitality in breast cancer survivors. Study Details In the study, 200 women with stage 0 to IIIA breast cancer who had completed...
Cognitive-Behavioral Therapy Plus Hypnosis Controls Fatigue in Breast Cancer Patients Receiving Radiotherapy
In a study reported in the Journal of Clinical Oncology, Montgomery et al found that an intervention consisting of cognitive-behavioral therapy plus hypnosis produced better control of fatigue than supportive meetings with trained interventionists for women undergoing radiotherapy for breast...
Addition of Nintedanib to Docetaxel Improves Progression-Free Survival as Second-Line Treatment in NSCLC
In a phase III trial (LUME-Lung 1) reported in The Lancet Oncology, Reck et al assessed the addition of nintedanib to docetaxel in second-line treatment of non–small cell lung cancer (NSCLC). The combination significantly improved progression-free survival in all patients and improved overall ...
Multiple Myeloma Study Shows Widespread Genetic Heterogeneity
A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...
Elevated Plasma Vitamin B12 Levels Associated With Cancer Risk
High plasma levels of vitamin B12 (cobalamin) have been reported in patients with cancer of different types. In a Danish study reported in the Journal of the National Cancer Institute, Arendt et al assessed cancer risk in subjects presenting with elevated cobalamin. They found that cancer risk...
No Benefit From Adding Cetuximab to Pemetrexed in Recurrent/Progressive NSCLC After Platinum-Based Therapy
In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...
Most Gastroenterologists and Endoscopy Nurses Prefer Propofol Over Moderate Sedation in Screening Colonoscopies, but Would Pay Little Extra for It
Propofol is increasingly being used for sedation in screening colonoscopies in low-risk patients. In the United States, propofol can be administered only by an anesthesiologist, which can raise the cost of the procedure by $600 to $2,000. In a study reported in a research letter in JAMA Internal...
Perioperative FOLFOX4 Does Not Improve Overall Survival vs Surgery Alone in Patients With Resectable Liver Metastases From Colorectal Cancer
Previously reported results of the phase III EORTC intergroup 40983 trial showed that perioperative chemotherapy with FOLFOX4 (leucovorin, fluorouracil [5-FU], and oxaliplatin) increased progression-free survival compared with surgery alone in patients with initially resectable liver metastases...
Addition of Vintafolide to Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer
In a randomized phase II trial reported in the Journal of Clinical Oncology by R. Wendel Naumann, MD, of Carolinas Medical Center in Charlotte, North Carolina, and colleagues, the addition of vintafolide to pegylated liposomal doxorubicin improved progression-free survival in women with...
Increased Risk of Long-Term Cardiovascular Mortality and All-Cause Mortality in Patients With Differentiated Thyroid Carcinoma
In a study reported in the Journal of Clinical Oncology, Esther N. Klein Hesselink, of University Medical Center Groningen in the Netherlands, and colleagues evaluated long-term cardiovascular mortality in patients with differentiated thyroid cancer. They found that risk of cardiovascular and...
No Benefit of Dose-Dense vs Standard Temozolomide in Newly Diagnosed Glioblastoma, MGMT Methylation Associated With Better Survival
Dose-dense temozolomide results in depletion of O6-methylguanine-DNA methyltransferase (MGMT)—a potential determinant of treatment response—in blood mononuclear cells and possibly in tumors. In a phase III trial (Radiation Therapy Oncology Group [RTOG] 0525) reported in the Journal ...
Oral CMX001 100 mg Twice Weekly Reduces Cytomegalovirus Events in Patients Receiving Hematopoietic Cell Transplants
The anti-cytomegalovirus agent CMX001 is an oral lipid acyclic nucleoside phosphonate that is absorbed in the small intestine and transported throughout the body as a phospholipid. It is converted intracellularly to cidofovir diphosphate, but unlike cidofovir, is not a substrate of organic ion...
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
AACR Issues 2013 Cancer Progress Report
The American Association for Cancer Research (AACR) released its Cancer Progress Report 2013 today. And while there is much to celebrate in the significant progress made in cancer research—which has led to more effective therapies for the more than 200 types of cancer and increased...
Dana-Farber Mourns the Passing of Jane Carrie Weeks, MD, MSc, National Leader in Outcomes Research
Jane Carrie Weeks, MD, MSc, a prominent researcher at Dana-Farber Cancer Institute, internationally known for building the discipline of outcomes research in oncology and admired by colleagues as an outstanding mentor, died September 10 after a long illness. She was "one of the true intellectual...
Versatile MicroRNAs Block Cancer Blood Supply, Suppress Metastasis
A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center reported in Nature Communications. Patients with lung, ovarian, kidney, or...
FLT3 Inhibitor Quizartinib Shows Activity in Relapsed/Refractory AML
Internal tandem duplications (ITDs) in the FMS-like tyrosine kinase 3 (FLT3) juxtamembrane region are observed in 20% to 30% of patients with acute myeloid leukemia (AML), and point mutations in the FLT3 activation loop are observed in 5% to 10%. FLT3-ITD mutations are associated with early relapse ...
Survival Trend With Palliative FOLFOX4 vs Doxorubicin in Asian Patients With Advanced Hepatocellular Carcinoma
In a study reported in Journal of Clinical Oncology, Shukui Qin, MD, of People’s Liberation Army Cancer Centre, Bayi Hospital, in Nanjing, and colleagues compared FOLFOX4 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) with doxorubicin as palliative chemotherapy in patients with ...
No Overall Survival Benefit With Brivanib in Advanced Hepatocellular Carcinoma Patients After Sorafenib Failure or Intolerance
The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...
First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma
The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...
No Invasive Disease-Free Survival Benefit of Adding Bevacizumab to Adjuvant Chemotherapy in Triple-Negative Breast Cancer
In a study (the BEATRICE trial) reported in Lancet Oncology, David Cameron, MD, of the University of Edinburgh, and colleagues evaluated the strategy of adding the antiangiogenic agent bevacizumab (Avastin) to adjuvant chemotherapy in women with triple-negative breast cancer. The study showed that...
ASCO 2013: First Prospective Trial Shows Molecular Profiling Timely for Tailoring Therapy
A clinical trial has shown that patients and their physicians are eager to jump into the next generation of cancer care: analysis of an individual’s tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, were presented at the 2013 ASCO Annual Meeting...
